Form 4: United Therapeutics Exec Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock on April 6, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed a series of transactions on April 6, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The exercise of stock options occurred at a price of $146.03 per share, resulting in the acquisition of 9,500 shares.
• These acquired shares were then sold in multiple transactions at weighted average prices ranging from $552.37 to $566.00.
• These trades were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt directly beneficially owns 40,513 shares of common stock.
• Additionally, Rothblatt has indirect beneficial ownership of 324,518 shares held by a trust, 258,117 shares held by a trust where her spouse is trustee and beneficiary, 45,596 shares held by a trust where her spouse shares investment power, and 10,962 shares held by a trust where she is trustee and beneficiary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine insider transactions conducted under a pre-established plan, rather than indicating new strategic developments or significant shifts in the company's financial health.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and compliant approach to stock sales.
• The exercise of stock options at a lower price ($146.03) and sale at significantly higher market prices ($552.37 - $566.00) suggests a profitable execution of the plan.
• The reporting person continues to hold a substantial number of shares indirectly through various trusts, indicating ongoing investment in the company.

Negatives

• The sale of a significant number of shares by a key executive could be interpreted negatively by the market, although it is part of a pre-planned strategy.
• The weighted average sale prices indicate a series of sales over a period, suggesting a gradual divestment rather than a single large block sale.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of all remaining options, which could lead to future sales if the plan is not extended or completed.
• The reliance on stock options and their exercise could be subject to market volatility affecting the profitability of the plan.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until all 1,734,410 stock options are exercised, indicating potential for further transactions within this timeframe.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for various sales executed at weighted average prices.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO of a biotechnology company like United Therapeutics is common practice to manage stock sales in a way that avoids insider trading concerns, especially when dealing with potentially volatile stock prices common in the sector.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, may lead to short-term market perception shifts. However, the ongoing indirect ownership suggests continued alignment with shareholder interests.
• Employees: The transactions do not directly impact employee stock options or benefits but reflect the executive's compensation and investment strategy.
• Management: The use of a 10b5-1 plan demonstrates adherence to corporate governance best practices for insider trading compliance.

Next Steps

• Continue to monitor the execution of the 10b5-1 trading plan until its expiration or completion of option exercises.
• Observe any further filings related to beneficial ownership changes by Martine A. Rothblatt or other key executives.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, Common Stock, Insider Trading, 10b5-1 Plan, Martine Rothblatt, Beneficial Ownership, Stock Sale, Executive Compensation